Publications

Chi Y, DiKun KM, Tang X-H, Warren CD, Chikara S, Del Aguila EMere, Wagner JA, Geri JB, Gudas LJ.  2026.  Retinoic acid receptor β deletion in podocytes causes kidney and liver dysfunction, modeling nephrotic syndrome.. J Mol Endocrinol. 76(1)

Chi Y, DiKun KM, Tang X-H, Warren CD, Chikara S, Del Aguila EMere, Wagner JA, Geri JB, Gudas LJ.  2026.  Retinoic acid receptor β deletion in podocytes causes kidney and liver dysfunction, modeling nephrotic syndrome.. J Mol Endocrinol. 76(1)

Chi Y, Del Aguila EMere, Zhang T, Warren CD, Hoxie HR, Chen Q, Gross SS, Geri JB, Nanus DM, Gudas LJ.  2025.  ATF4 in proximal tubules modulates kidney function and modifies the metabolome.. J Mol Med (Berl).

Chi Y, Chikara S, Del Aguila EMere, Zhang T, Geri JB, Nanus DM, Gudas LJ.  2025.  Deletion of the transcription factor ATF4 in a model of clear cell renal cell carcinoma.. Neoplasia. 66:101188.

Harris AE, Lothion-Roy J, Thompson RL, Haque M, Woodcock CL, Alsaleem MA, Dean A, Kariri Y, Toss MS, Gudas LJ et al..  2025.  Functional and clinical significance of the RNA m6A methyltransferase complex in breast cancer.. NPJ Breast Cancer. 11(1):147.

Harris AE, Lothion-Roy J, Thompson RL, Haque M, Woodcock CL, Alsaleem MA, Dean A, Kariri Y, Toss MS, Gudas LJ et al..  2025.  Functional and clinical significance of the RNA m6A methyltransferase complex in breast cancer.. NPJ Breast Cancer. 11(1):147.

Del Aguila EMere, Tang X-H, Gudas LJ.  2025.  Retinoic acid receptor-β deletion in a model of early pancreatic ductal adenocarcinoma (PDAC) tumorigenesis.. Am J Cancer Res. 15(1):127-140.

Patke R, Harris AE, Woodcock CL, Thompson R, Santos R, Kumari A, Allegrucci C, Archer N, Gudas LJ, Robinson BD et al..  2024.  Epitranscriptomic mechanisms of androgen signalling and prostate cancer.. Neoplasia. 56:101032.

DiKun KM, Tang X-H, Fu L, Choi ME, Lu C, Gudas LJ.  2024.  Retinoic acid receptor α activity in proximal tubules prevents kidney injury and fibrosis.. Proc Natl Acad Sci U S A. 121(7):e2311803121.

Baquero J, Tang X-H, Ferrotta A, Zhang T, DiKun KM, Gudas LJ.  2024.  The transcription factor bmi1 increases hypoxic signaling in oral cavity epithelia.. Biochim Biophys Acta Mol Basis Dis. :167161.

Metzler VM, de Brot S, Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Nilsson EM, Ntekim A, Persson JL, Robinson BD et al..  2023.  The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer.. Front Cell Dev Biol. 11:1116424.

van der Mijn JC, Laursen KB, Fu L, Khani F, Dow LE, Nowak DG, Chen Q, Gross SS, Nanus DM, Gudas LJ.  2023.  Novel genetically engineered mouse models for clear cell renal cell carcinoma.. Sci Rep. 13(1):8246.

DiKun KM, Gudas LJ.  2023.  Vitamin A and retinoid signaling in the kidneys.. Pharmacol Ther. 248:108481.

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.

Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Metzler VM, Persson JL, Robinson BD, Khani F, Alsaleem M, Ntekim A et al..  2022.  The METTL3 RNA Methyltransferase Regulates Transcriptional Networks in Prostate Cancer.. Cancers (Basel). 14(20)

Del Aguila EMere, Tang X-H, Gudas LJ.  2022.  Pancreatic Ductal Adenocarcinoma: New Insights into the Actions of Vitamin A.. Oncol Res Treat.

van der Mijn JC, Chen Q, Laursen KB, Khani F, Wang X, Dorsaint P, Sboner A, Gross SS, Nanus DM, Gudas LJ.  2022.  Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR).. Mol Carcinog.

Williams RM, Shah J, Mercer E, Tian HS, Thompson V, Cheung JM, Dorso M, Kubala JM, Gudas LJ, de Stanchina E et al..  2021.  Kidney-Targeted Redox Scavenger Therapy Prevents Cisplatin-Induced Acute Kidney Injury.. Front Pharmacol. 12:790913.

Williams RM, Shah J, Mercer E, Tian HS, Thompson V, Cheung JM, Dorso M, Kubala JM, Gudas LJ, de Stanchina E et al..  2021.  Kidney-Targeted Redox Scavenger Therapy Prevents Cisplatin-Induced Acute Kidney Injury.. Front Pharmacol. 12:790913.

Laursen KB, Chen Q, Khani F, Attarwala N, Gross SS, Dow L, Nanus DM, Gudas LJ.  2021.  Mitochondrial Ndufa4l2 Enhances Deposition of Lipids and Expression of Ca9 in the TRACK Model of Early Clear Cell Renal Cell Carcinoma.. Front Oncol. 11:783856.

Molina AM, van der Mijn JC, Christos P, Wright J, Thomas C, Dutcher JP, Nanus DM, Tagawa ST, Gudas LJ.  2020.  NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.. Invest New Drugs.

van der Mijn JC, Awamlh BAl Hussein, Khan AIslam, Posada-Calderon L, Oromendia C, Fainberg J, Alshak M, Elahjji R, Pierce H, Taylor B et al..  2019.  Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series.. PLoS One. 14(12):e0226285.

Simandi Z, Horvath A, Wright LC, Cuaranta-Monroy I, De Luca I, Karolyi K, Sauer S, Deleuze J-F, Gudas LJ, Cowley SM et al..  2016.  OCT4 Acts as an Integrator of Pluripotency and Signal-Induced Differentiation.. Mol Cell. 63(4):647-661.

Simandi Z, Horvath A, Wright LC, Cuaranta-Monroy I, De Luca I, Karolyi K, Sauer S, Deleuze J-F, Gudas LJ, Cowley SM et al..  2016.  OCT4 Acts as an Integrator of Pluripotency and Signal-Induced Differentiation.. Mol Cell. 63(4):647-661.

Kauffman EC, Robinson BD, Downes M, Marcinkiewicz K, Vourganti S, Scherr DS, Gudas LJ, Mongan NP.  2013.  Estrogen receptor-β expression and pharmacological targeting in bladder cancer.. Oncol Rep. 30(1):131-8.